Biogen Inc. (FRA:IDP)
128.30
+0.40 (0.31%)
Last updated: Oct 23, 2025, 10:58 AM CET
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,119,322
Profits / Employee
€171,364
Market Cap
18.96B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
| Siemens Healthineers AG | 72,000 |
Biogen News
- 1 day ago - Biogen (BIIB) Highlights Promising Results of Dapirolizumab Pegol in Lupus Studies - GuruFocus
- 1 day ago - Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 - GlobeNewsWire
- 4 days ago - J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround - Nasdaq
- 6 days ago - Biogen (BIIB) Gains Momentum with Patient Opportunity Equity Strategy - GuruFocus
- 6 days ago - Patient Opportunity Equity strategy buys UNH, CROX, MAT, IAC, and BIIB - Seeking Alpha
- 7 days ago - Why InnoCare's Licensing Deal Triggered A Stock Rout - Benzinga
- 9 days ago - Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact - GuruFocus
- 9 days ago - Biogen sees negative impact on Q3 EPS from IPR&D expense - Seeking Alpha